Schedule 13G ownership disclosure

REVANCE THERAPEUTICS INC

Security class unavailable · CUSIP: 761330109

Event date: 2018-03-30

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
3,814,034
Percent of class
10.3800%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902219-18-000444
Form type
SC 13G/A
Filer
Revance Therapeutics, Inc.
CIK
CIK 1479290
Filed
Apr 10, 2018
Reporting period
Mar 30, 2018
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub